✦ LIBER ✦

TNF-α inhibitors: `new era' of biological therapies for RA?

Book ID: 120868192
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2000
Weight: 151 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200012670-00004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Synthesis of new TNF-α Inhibitors and th

Synthesis of new TNF-α Inhibitors and their biological properties

✍ Norio Fujiwara; Yutaka Ueda; Naohito Ohashi 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 309 KB

ChemInform Abstract: Synthesis of New TN

ChemInform Abstract: Synthesis of New TNF-α Inhibitors and Their Biological Properties.

✍ N. FUJIWARA; Y. UEDA; N. OHASHI 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 31 KB

Administration of tumor necrosis factor

Administration of tumor necrosis factor α (TNFα) inhibitors after exposure to TNFα prevents development of the maximal biological effect: An argument for clinical treatment with TNFα inhibitors

✍ Ingeborg Engelberts; Achim Möller; Jet F.M. Leeuwenberg; Cees J. van der Linden; 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 591 KB

Design, synthesis and biological evaluat

Design, synthesis and biological evaluation of new thalidomide analogues as TNF-α and IL-6 production inhibitors

✍ Charlotte Chaulet; Cécile Croix; David Alagille; Sylvain Normand; Adriana Delwai 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 620 KB

Several thalidomide analogues were synthesized and compared to thalidomide and its more active analogue, lenalidomide, for their ability to inhibit the production of the pro-inflammatory cytokine tumour necrosis factor (TNF)-α and interleukin (IL)-6 by LPS-activated peripheral blood mononuclear cell

TUMOUR NECROSIS FACTOR α (TNF-α) INTERFE

TUMOUR NECROSIS FACTOR α (TNF-α) INTERFERES WITH Fas-MEDIATED APOPTOTIC CELL DEATH ON RHEUMATOID ARTHRITIS (RA) SYNOVIAL CELLS: A POSSIBLE MECHANISM OF RHEUMATOID SYNOVIAL HYPERPLASIA AND A CLINICAL BENEFIT OF ANTI-TNF-α THERAPY FOR RA

✍ Shiro Ohshima; Toru Mima; Mitsuko Sasai; Katsuhiro Nishioka; Masatoshi Shimizu; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 868 KB

Downregulation of survivin and aurora A

Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy

✍ Anat Biran; Michael Brownstein; Ronit Haklai; Yoel Kloog 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 892 KB

## Abstract Histone deacetylase (HDAC) inhibitors, such as valproic acid (VPA), constitute a novel class of anticancer agents that cause an increase in acetylated histones and thus restore the expression of dormant tumor‐suppressor and other genes related to cell differentiation, cell‐cycle arrest